{"schema_version":"secwatch.filing_event.v1","accession":"0001728117-24-000086","form_type":"8-K","ticker":"GOSS","cik":"0001728117","company_name":"Gossamer Bio, Inc.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.329017+00:00","generated_at":"2026-05-31T10:05:00.558899+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Gossamer Bio Q2 2024 net income $49.2M; cash $354.5M; Chiesi collaboration on track","bullets":["Net income $49.2M ($0.22 basic EPS) vs net loss $42.5M in Q2 2023.","Cash, cash equivalents & marketable securities $354.5M as of June 30, 2024; runway into H1 2027.","Revenue from Chiesi collaboration: $88.8M license sale + $7.1M R&D services.","R&D expenses $35.1M (vs $36.3M); G&A expenses $8.7M (vs $10.0M).","PROSERA Phase 3 PAH trial enrollment ongoing; top-line results expected Q4 2025; Phase 3 PH-ILD trial to start mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001728117-24-000086","json":"https://secwatch.observer/filing/0001728117-24-000086.json","markdown":"https://secwatch.observer/filing/0001728117-24-000086.md","text":"https://secwatch.observer/filing/0001728117-24-000086.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728117/000172811724000086/0001728117-24-000086-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728117/000172811724000086/goss-20240812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:05:00.558899+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}